NCT03816631View on ClinicalTrials.gov

A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 28, 2019

Primary Completion Date

April 27, 2020

Study Completion Date

April 27, 2020

Conditions
Hepatic Impairment
Interventions
DRUG

Pimodivir

Participants will receive single oral dose of Pimodivir 600 mg (2\*300 mg tablets) under fasted condition on Day 1.

Trial Locations (2)

24105

CRS Clinical Research Services Kiel GmbH, Kiel

81241

APEX GmbH, München

Sponsors
All Listed Sponsors
lead

Janssen-Cilag International NV

INDUSTRY

NCT03816631 - A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment | Biotech Hunter | Biotech Hunter